Seventeen-Year Journey Working With a Master

Jinfang Zhu*

Molecular and Cellular Immunoregulation Section, Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States

It had been a great honor for me to work with the late Dr. William E. Paul for 17 years in the Laboratory of Immunology (LI) from 1998 until his passing in 2015. He was such a master in the immunology field. Under his outstanding guidance, my research has been focusing on transcriptional regulation of T helper (Th) cell differentiation, especially, on the role of a master transcription factor GATA3 during Th2 cell differentiation. Just as enormous scientific contributions of Dr. Paul (we all call him Bill) to the immunology community are far beyond his serving as the Chief of the LI, GATA3 also plays important roles in different lymphocytes at various developmental stages besides its critical functions in Th2 cells. In this special review dedicated to the memory of Bill, I will summarize the research that I have carried out in Bill's lab working on GATA3 in the context of related studies by other groups in the field of T cell differentiation and innate lymphoid cell (ILC) development. These include the essential role of GATA3 in regulating Th2/ILC2 differentiation and their functions, the critical role of GATA3 during the development of T cells and innate lymphoid cells, and dynamic and quantitative expression of GATA3 in controlling lymphocyte homeostasis and functions.

Keywords: GATA transcription factor, T helper cells, innate lymphoid cells, cytokines, T cell differentiation, T cell development

PREFACE

I joined the lab of Dr. William E. Paul (Bill) in 1998 as a postdoctoral fellow soon after I got my Ph.D. degree from the Shanghai Institute of Biochemistry, Chinese Academy of Sciences. Before I arrived in the U.S., Bill and I had already exchanged several emails regarding my potential projects. As a scientist who discovered interleukin (IL)-4, Bill had always been interested in IL-4 signaling and the structure of IL-4 receptor (IL-4R). He initially suggested me to crystallize the intracellular domains of the IL-4Rα chain, but I was more interested in transcriptional regulation of gene expression in lymphocytes, an area no one in Bill’s lab had explored in the past. Bill later asked several other postdocs, who joined his lab after me, to work on IL-4R structure demonstrating his amazing persistence in research and impressive flexibility in mentoring.

Since IL-4 is the critical cytokine for driving type 2 T helper (Th2) cell differentiation (1), my first project started with searching for IL-4-inducible transcription factor(s) during early Th2 cell differentiation using DNA microarray. At the same time, I was working on the cross-regulation of T cell receptor (TCR)- and IL-4-mediated signaling (2) together with Dr. Hua Huang, a senior postdoc in Bill's lab at that time, who is now a full professor at the National Jewish Health.

My first project ended up with identifying growth factor independent-1 (Gfi-1) as an IL-4-inducible transcription factor, which plays an important role in promoting selective growth of committed Th2 cells (3). Later, Gfi-1 was also reported to suppress Th1, Th17, and Treg cell differentiation and the expression of IL-7 receptor α chain (4–6). The reason why we focused on transcription factors
that are induced by IL-4 at early stages of Th2 cell differentiation is mainly because, in 1997, Drs. Richard Flavell and Anuradha Ray’s groups had already independently reported that GATA3 is necessary and sufficient for the expression of Th2 cytokines (7, 8).

In our initial report, the effect of Gfi-1 on Th2 cell proliferation was demonstrated by retroviral co-expression of Gfi-1 and GATA3 (3). To further assess whether Gfi-1 indeed plays an important role during Th2 responses under physiological conditions, with the help of Dr. Hua Gu who was a new Principle Investigator in the LI at that time, I started to generate Gfi-1 conditional knockout mice (4). At that time, GATA3 conditional knockout mice were not available either. While I was making Gfi-1 floxed mice, Bill gave me a very important suggestion—why don’t you also prepare LI at that time, I started to generate Gfi-1 conditional knockout mice with the help of Dr. Hua Gu who was a new Principle Investigator in the LI role during Th2 responses under physiological conditions, with Bill—always focusing on the most important things—has had a great impact on my research career.

**INTRODUCTION**

CD4 Th cells orchestrate adaptive immune responses by producing effector cytokines. In order to effectively exert their protective functions during infections, distinct Th subsets are developed to deal with a variety of pathogens (10–12). There are three major Th cell subsets: type 1 T helper (Th1) cells that mainly produce IFN-γ, Th2 cells that produce IL-4, IL-5, and IL-13, and Th17 cells that produce IL-17a and IL-17f (13, 14). Th1 cells are important for immune responses to intracellular bacteria and viruses; Th2 cells are mainly responsible for immunity against helminth infections; whereas Th17 cells are essential for dealing with infections with extracellular bacteria and fungi. Besides their critical roles in mediating protective immunity, Th subsets are also capable of inducing many types of inflammatory responses. While Th2 cells are known to be involved in allergic diseases, Th1 and Th17 cells may cause autoimmunity (12, 15). All the Th effector cells are developed from naïve CD4 T cells when they encounter an antigen/MHCII complex that can be recognized by their antigen-specific TCR. Some naïve CD4 T cells may differentiate into regulatory T cells (Tregs) and they are regarded as peripheral induced Tregs (pTregs); together with thymic-derived Tregs, pTregs regulate the magnitude and duration of a particular immune response in addition to their essential role in maintaining immune tolerance (16–20).

In recent years, a group of non-B non-T lymphocyte-like cells that are capable of producing Th effector cytokines have drawn much attention in the field. These cells are now designated as innate lymphoid cells (ILCs) (21–24). Just like Th cells, there are three major ILC subsets: group 1 ILCs (ILC1s) that mainly produce IFN-γ, ILC2s that produce IL-5 and IL-13, and ILC3s that mainly produce IL-22. Since ILC subsets can produce cytokines known to be effector cytokines of Th cells, ILC and Th subsets of the same group are involved in related type of immune responses in a collaborative manner (25–30). For example, just as Th2 cells, ILC2s are not only involved in immune responses against helminth infections, but also induce allergic inflammation (29, 31–38). Therefore, similar to Th cells serving as professional cytokine-producing cells, ILCs are considered as the innate counterparts of Th cells.

The differentiation of Th1, Th2, and Th17 cells is mainly controlled by cytokine environment during their activation, which
induces the expression of lineage-defining transcription factors: T-bet for Th1; GATA3 for Th2; and RORγt for Th17 cells (39). These master regulators are not only essential for the differentiation and functions of Th subsets, but also they are utilized by ILC subsets for their development and functions: T-bet for ILC1s; GATA3 for ILC2s; and RORγt for ILC3s. While T-bet and RORγt are selectively expressed by Th1/ILC1 and Th17/ILC3 subsets, respectively, GATA3 is actually expressed by all the Th and ILC subsets although its expression in Th2 cells and ILC2s is the highest. Furthermore, GATA3 is dynamically expressed during T cell and ILC development. In this mini-review, I will discuss multiple important functions of this master transcription factor in a variety of lymphocytes at different developmental stages (Table 1).

CRITICAL ROLE OF GATA3 IN TH2 DIFFERENTIATION AND FUNCTIONS

As mentioned earlier, Drs. Flavell and Ray’s groups independently reported that GATA3 is a key transcription factor for inducing Th2 cytokine expression back in 1997 (7, 8). Soon after, Dr. Ken Murphy’s group further showed that enforced expression of retroviral GATA3 induces endogenous GATA3 expression even in cells that were cultured under Th1 polarization conditions (40, 41). However, because GATA3-deficient CD4 T cells were not available at that time, direct evidence to support the essential role of GATA3 during Th2 differentiation particularly in vivo was still lacking. Nevertheless, these exciting reports inspired Bill and me to prepare a conditional knockout allele of Gata3 by the Cre-loxP system (42). By using Gata3 conditional knockout mice, both Dr. I-Cheng Ho’s group and ours confirmed that GATA3 indeed is the master regulator of Th2 cells (9, 43). In the absence of GATA3, the production of Th2 cytokines is severely impaired, at the same time, IFN-γ production is induced even when the cells are cultured under Th2 conditions (44).

Interleukin-4-mediated STAT6 activation is sufficient to induce GATA3 expression during Th2 cell differentiation (45). Low dose of TCR stimulation can also upregulate GATA3 expression in the absence of IL-4 signaling (46). Indeed, Th2 differentiation may occur in vivo in an IL-4-STAT6-independent manner (15). On the other hand, although GATA3 can autoregulate its own expression, GATA3 is not required to induce itself in the presence of IL-4 signaling (47). Nevertheless, IL-4-dependent as well as IL-4-independent Th2 cell differentiation depends on GATA3 both in vitro and in vivo (9).

Genome-wide analyses of GATA3 binding through ChIP-Seq (chromatin immune-precipitation followed by high throughput sequencing) show that GATA3 binds to the Th2 cytokine locus Il4/Il13 at multiple sites including sites in the Il4 intron 2, the Il13 promoter, and the locus control region within the Rad50 gene (47). GATA3 also binds to the promoter of the Il5 genes (48, 49). A major mechanism for GATA3 to induce IL-4 expression is through chromatin remodeling at the Il4/Il13/Rad50 locus. In mature Th2 cells in which GATA3-mediated epigenetic modifications within the Th2 cytokine locus have already occurred, GATA3 is no longer needed for IL-4 production. However, since the activity of the Il5 and Il13 promoters always depends on GATA3, GATA3 deletion at any time completely abolishes IL-5 and IL-13 expression (9). Many other Th2-specific genes as well as long intergenic non-coding RNAs are also directly regulated by GATA3 (50). For example, T1/ST2, the IL-33 receptor encoded by the Il1rl1 gene, is highly expressed in the most mature Th2 cells and GATA3 binds to the Il1rl1 gene (47, 50).

CRITICAL ROLE OF GATA3 IN ILC2 DEVELOPMENT AND FUNCTION

When I started my own research group, it had been known that there are a group of non-T non-B innate-like lymphocytes capable of producing type 2 cytokines and that type 2 cytokines produced by CD4 T cells are not essential for host defense (29, 33). Thus, I was very interested in what these cells were and how they developed. We hypothesized that GATA3, the critical factor for type 2 immune responses, may also be functionally important for the generation of type 2 cytokine-producing innate-like lymphocytes. Thus, we started to generate mice with GATA3 deficiency in the hematopoietic system and mice allowing inducible GATA3 deletion.

These innate-like cells are now known as type 2 innate lymphoid cells (ILC2s). Indeed, ILC2s express very high levels of GATA3 and they are highly enriched in the lung, skin, gut, and adipose tissues (21, 31, 35). Strikingly, ILC2s and Th2 cells generated during helminth infection are identical in their transcriptomes (51). Just as its critical function for Th2 cell differentiation, GATA3 is presumably also important for ILC2 development. However, due to its essential role during ILC development in the progenitor stage, which I will discuss later, definitive evidence showing the importance of GATA3 expression for ILC2 development is still lacking. Nevertheless, even in mature ILC2s, deletion of GATA3 results in loss of ILC2 functions (i.e., diminished IL-5 and IL-13 production) and reduced survival of ILC2s (52–57). Genome-wide analysis comparing transcriptomes between wild type ILC2s and GATA3-deficient “ILC2s” indicates that several important genes involved in type 2 immune responses, such as Il5, Il13, Il1rl1, and Ccr8, etc., are regulated by GATA3 (54). These genes are also regulated by GATA3 in mature Th2 cells, which may explain similar functionalities between ILC2s and Th2 cells.

GATA3 also directly binds to the Il4/Il13 loci in ILC2s; the pattern of GATA3 binding to the Th2 cytokine locus in ILC2s is very similar to that in Th2 cells (47, 58). It has been reported that GATA3 regulates chromatin remodeling at several Th2-specific gene loci in Th2 cells (47), however, whether GATA3 play a similar role in epigenetic modifications in ILC2s is unknown. GATA3 also regulated the expression of the IL-33 receptor subunit T1/ST2 and IL-25R in ILC2s (47, 54, 58). Therefore, because of the downregulation of IL-33R and IL-25R expression in GATA3-deficient “ILC2s”, these cells fail to respond to either IL-33 or IL-25. GATA3-deficient “ILC2s” also express lower levels of CD25 and IL-7R. Thus, there is a general defect of GATA3-deficient ILC2s in response to multiple cytokines.

Frontiers in Immunology | www.frontiersin.org 3 May 2018 | Volume 9 | Article 960
CRITICAL ROLE OF GATA3 IN T CELL AND ILC DEVELOPMENT

Besides its essential function in Th2 cells and ILC2s, GATA3 is also critical for T cell and ILC development at multiple stages (59, 60). GATA3 is important for the generation of T cell progenitors (59, 61). GATA3 is also required for CD4 but not for CD8 T cell development (47, 59, 62–64). Similarly, GATA3 is critical for the development of T helper-like ILCs that express IL-17Ra, but not of NK cells (54). In fact, high levels of GATA3 expression are required for the generation of PLZF/PD-1-expressing non-LTI progenitors but low levels of GATA3 expression are necessary for the function of LTI cells (65). Therefore, helper-like ILCs are considered as the innate counterpart of CD4 Th cells, whereas NK cells resemble innate CD8-like cells, and GATA3 is a master regulator for the development of both innate (ILC) and adaptive (Th) lymphocytes.

CRITICAL FUNCTIONS OF GATA3 IN Tregs

GATA3 is also expressed by Tregs, and under certain circumstances, GATA3 expression may reach high levels, especially when cells receive IL-4 and/or TCR stimulation (66). The expression of some “Th2-related” genes, including Il1r1I and Ccr8, in Tregs depends on GATA3 (47). GATA3 binds to the Foxp3 locus at the CNS2 region (67) and such binding may be important for maintaining optimal Foxp3 expression in Tregs (66, 68). Deletion of GATA3 specifically in Treg cells results in uncontrolled systemic Th2 responses in one study (68), however, other studies reported that these GATA3 conditional knockout mice were grossly normal although the GATA3-deficient Tregs showed some abnormal phenotype (66, 69, 70). Interestingly, GATA3 is dynamically expressed by Treg cells (70). Because persistent expression of GATA3 in Tregs at high levels may convert Tregs into Th2 cells (71), dynamic expression of GATA3 may be critical for maintaining Treg phenotype. Together with T-bet, GATA3 also suppresses RORγt expression in Tregs. Therefore, balanced expression of T-bet, GATA3, and RORγt in Foxp3-expressing is critical for Treg-mediated immune regulation (70).

IMPORTANT FUNCTIONS OF GATA3 IN OTHER LYMPHOCYTES

GATA3 is expressed by ILC3s at intermediate levels (58). Interestingly, intermediate levels of GATA3 expression are required for regulating the balance between T-bet and RORγt, and thus the development of Nkp46+ ILC3s (58). GATA3 also regulates IL-22 expression in ILC3s (58). Whether GATA3 regulates the balance between T-bet and RORγt and/or IL-22 production in Th cells requires further investigation. GATA3 is also expression by ILC1s at intermediate levels and GATA3 is required for maintaining ILC1 homeostasis (26, 58). GATA3 is also expressed by NK cells but at low levels. Although GATA3 is not required for the development of conventional NK cells, it affects their maturation and cytokine production (54, 72, 73). GATA3 also affects NKT cell development and functions (74, 75) as well as CD8 T cell homeostasis partly through regulating IL-7Rα expression (76). Furthermore, GATA3 expression is found at low levels in Th1 and Th17 cells; however, its functions in these cells require further investigation.

RELATIONSHIP BETWEEN GATA3 AND OTHER IMPORTANT TRANSCRIPTION FACTORS

During Th2 differentiation, GATA3 can be upregulated by IL-4/STAT6 and/or TCR-mediated signaling (15). However, ILC2 development does not require IL-4/STAT6 signaling. It is possible that Notch signaling plays an important role in GATA3 induction in ILCs. Consistent with this notion, TCF7, a transcription factor induced by Notch signaling, can upregulate GATA3 expression in ILC progenitors (56, 77). What induces/maintains high GATA3 expression in ILC2s is not known.

Although GATA3 plays an essential role in the development and functions of ILC and Th cell subsets, many other transcription factors, including Id2, TCF7, Foxp3, and Th-POK may form a network with GATA3 in determining cell lineage fates (26, 63, 77, 78). Just as GATA3, Bcl11b is important for the development of T cells and ILC2s (79–84). We have recently reported that GATA3 and Bcl11b form a complex and they co-localized in many enhancer regions within the Th1- and Th2-related genes (85). Interestingly, the GATA3/Bcl11b complex not only suppresses the expression of many Th1-related genes, but it also controls the magnitude of Th2 responses. GATA3 and Bcl11b may have common targets in ILC2s, which requires further investigation.

Several other transcription factors can also interact with GATA3. T-bet interacts with GATA3 and suppresses its function (86, 87). Consequently, T-bet and GATA3 co-bind to many Th1- or Th2-related genes (88–90). T-bet overexpression suppresses GATA3 expression at the transcription level (87). Endogenous expression of T-bet may also inhibit a GATA3-mediated “default” Th2 program during Th1 cell differentiation (90). Interestingly, T-bet is detected in GATA3 expressing cells during helminth infection to limit Th2 responses (91). On the other hand, GATA3 may silence the Tbx21 gene during Th2 cell differentiation (47). GATA3 may also inhibit Th1 differentiation by suppressing the expression of STAT4 expression as well as Runx3-mediated induction of IFN-γ expression (44, 92), and GATA3 can bind to Runx3 at the protein level.

CONCLUSION AND FUTURE DIRECTIONS

Bill was the master of the Laboratory of Immunology at the NIAID, NIH. I had learned tremendously from him through weekly one-on-one meetings throughout the 17-year period working with him. In the earlier era, Bill had also trained many world renowned immunologists, including Drs. Charles Janeway, Mark Davis, Laurie Glimcher, and Ronald Schwartz. Not only Bill had trained many incredible scientists in his lab, but also he had a great impact on our immunology community at the NIH and around the world. Thus, Bill is a true master of immunology. Without him, the NIH immunology interest group has been
suffering from a “knockout” phenotype in the past 2 years. We sincerely hope that a master(s) with his/her knowledge and ability equivalent to Bill’s will inspire our community again in the near future.

The master regulator for Th2 cells is GATA3. Just like Bill who contributed to the immunology field in many aspects, GATA3 also plays an essential role during early T cell development, CD4 T cell development as well as ILC development. In mature lymphocytes, ILC2s followed by Th2 cells express the highest levels of GATA3, which is consistent with its critical function in maintaining the functionalities of these type 2 lymphocytes. In other lymphocytes, including Tregs, NKT cells, CD8 T cells, ILC1s, ILC3s, NK cells, and possibly Th1 and Th17 cells, GATA3 may also regulate their homeostasis and functions (Table 1). GATA3-mediated IL-7Rα induction may be a common mechanism through which GATA3 regulates lymphocyte homeostasis; however, this may not fully explain the multifunctions of GATA3 during T cell and ILC development (58, 76).

Because GATA3 is expressed by all T cell and ILC subsets, and its expression varies from cell type to cell type and from stage-to-stage, the functions of GATA3 in different lymphocytes at various developmental and activation stages may be controlled by its expression levels and its interacting partners. Quantitative expression of GATA3 may result in a qualitative effect. To study GATA3 dose effect, a model with a titratable GATA3 expression may be needed to separate the differential roles of GATA3 expressed at high or low levels during the development of T cells and ILCs. Distinct complexes containing GATA3 in different cell types may offer cell-type-specific gene regulation. Thus, identifying GATA3-interacting proteins in different lymphocytes will help us understand the mechanisms of GATA3-mediated gene regulation, which will guide us to obtain deeper insights into the biology of the immune responses in allergic, infectious, autoimmune, and other inflammatory diseases.

We have recently generated a new GATA3 reporter mouse strain through the CRISPR/Cas9 technology by inserting a ZsGreen-T2A cassette into the Gata3 conditional allele flanked by two LoxP sites. This novel reporter works beautifully: variable GATA3 expression ranging for several logs in GFP intensity is observed in distinct lymphocytes at different developmental stages. We are using this mouse strain in combination with different Cre transgenic lines to study the function of this master regulator in a variety of lymphocytes particularly in vivo. We will be happy to share this valuable mouse strain with other labs that are interested in using it, even before its publication, as Bill had taught us the right way to promote science. Although Bill is no longer with us, and I cannot discuss our new exciting results with him anymore, my fascination in studying “master regulators” inspired by Bill will continue endlessly and I believe that what Bill had hoped for the new generation(s) of immunologists.

AUTHOR CONTRIBUTIONS

The author confirms being the sole contributor of this work and approved it for publication.

FUNDING

JZ is supported by the Division of Intramural Research (DIR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), USA (grant number 1-ZIA-A1001169).

REFERENCES

1. Le Gros G, Ben-Sasson SZ, Seder R, Finkelman FD, Paul WE. Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro: IL-2 and IL-4 are required for in vitro generation of IL-4-producing cells. J Exp Med (1990) 172:921–9. doi:10.1084/jem.172.3.921
2. Zhu J, Huang H, Guo L, Stonehouse T, Watson CJ, Hu-Li J, et al. Transient inhibition of interleukin 4 signaling by T cell receptor ligation. J Exp Med (2000) 192:1125–34. doi:10.1084/jem.198.8.1125
3. Zhu J, Guo L, Min B, Watson CJ, Hu-Li J, Young HA, et al. Growth factor independent-1 induced by IL-4 regulates Th2 cell proliferation. Immunity (2002) 16:733–44. doi:10.1016/S1074-7613(02)00317-5
4. Zhu J, Jankovic D, Grinberg A, Guo L, Paul WE. Gfi-1 plays an important role in IL-2-mediated Th2 cell expansion. Proc Natl Acad Sci U S A (2006) 103:18214–9. doi:10.1073/pnas.0608981103
5. Zhu J, Davidson TS, Wei G, Jankovic D, Cui K, Schones DE, et al. Down-regulation of Gfi-1 expression by TGF-beta is important for differentiation of Th17 and CD103+ inducible regulatory T cells. J Exp Med (2009) 206:329–41. doi:10.1084/jem.20081666
6. Chandele A, Joshi NS, Zhu J, Watson CJ, Guo L, Stonehouse T, et al. Conditional deletion of Gata3 shows its essential function in T(H)1-T(H)2 responses. Nat Immunol (2004) 5:1157–65. doi:10.1038/ni1128
7. Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol (2002) 2:933–44. doi:10.1038/nri954
8. Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood (2008) 112:1557–69. doi:10.1182/blood-2008-05-158154
9. Zhu J, Min B, Hu-Li J, Watson CJ, Grinberg A, Wang Q, et al. Conditional deletion of Gata3 shows its essential function in T(H)1-T(H)2 responses. Nat Immunol (2004) 5:1157–65. doi:10.1038/ni1128
10. Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol (2002) 2:933–44. doi:10.1038/nri954
11. Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood (2008) 112:1557–69. doi:10.1182/blood-2008-05-158154
12. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol (2010) 28:445–89. doi:10.1146/annurev-immunol-030409-101212
13. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol (1986) 136:2348–57.
14. Beaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol (2007) 25:821–52. doi:10.1146/annurev.immunol.25.020206.140155
15. Paul WE, Zhu J. How are T(H)2-type immune responses initiated and amplified? Nat Rev Immunol (2010) 10:225–35. doi:10.1038/nri2735
16. Chen W, Lin W, Hardegen N, Lei KJ, Li L, Marinos N, et al. Conversion of peripheral CD4+CD25+ naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med (2003) 198:1875–86. doi:10.1084/jem.20030152
17. Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity (2009) 30:636–45. doi:10.1016/j.immuni.2009.04.010
18. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol (2010) 10:490–500. doi:10.1038/nri2785
19. Josefiwicz SZ, Lu LE, Rudensky AY. Regulatory T cell mechanisms of differentiation and function. Annu Rev Immunol (2012) 30:531–64. doi:10.1146/annurev-immunol-032210-141623
20. Abbas AK, Benoist C, Bluestone JA, Campbell DJ, Ghosh S, Horii S, et al. Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol (2013) 14:307–8. doi:10.1038/ni.2554
21. Artis D, Spits H. The biology of innate lymphoid cells. Nature (2015) 517:293–301. doi:10.1038/nature14189
22. Diefenbach A, Colonna M, Koyasu S. Development, differentiation, and diversity of innate lymphoid cells. Immunity (2014) 41:354–65. doi:10.1016/j.immuni.2014.09.005
23. McKenzie AN, Spits H, Eberl G. Innate lymphoid cells in inflammation and immunity. Immunity (2014) 41:366–74. doi:10.1016/j.immuni.2014.09.006
24. Klose CS, Artis D. Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis. Nat Immunol (2016) 17:765–74. doi:10.1038/ni.3476
25. Kowalski OI, Collins PL, Celli M, Rabinette ML, Porter SI, Pyfrom SC, et al. Distinct gene regulatory pathways for human innate versus adaptive lymphoid cells. Cell (2016) 165:1134–46. doi:10.1016/j.cell.2016.04.014
26. Klose CS, Flach M, Mohle L, Rogell L, Hooyer T, Eberl K, et al. Differentiation of type 1 ILCs from a common progenitor to all helper-like innate lymphoid cell lineages. Cell (2014) 157:340–56. doi:10.1016/j.cell.2014.03.030
27. Sano T, Huang W, Hall JA, Yang Y, Chen A, Gavzy SJ, et al. An IL-23R/IL-22 circuit regulates epithelial serum amyloid A to promote local effector Th17 responses. Cell (2015) 163:381–93. doi:10.1016/j.cell.2015.08.061
28. Qin J, Guo X, Chen ZM, He L, Sonnenberg GF, Artis D, et al. Group 3 innate lymphoid cells inhibit T-cell-mediated intestinal inflammation through aryl hydrocarbon receptor signaling and regulation of microflora. Nature (2013) 39:386–99. doi:10.1038/nature13002
29. Price AE, Liang HE, Sullivan BM, Reinhardt RL, Eley SJ, Erle DJ, et al. Systemically depressed innate IL-13-expressing cells in type 2 immunity. Proc Natl Acad Sci U S A (2010) 107:11489–94. doi:10.1073/pnas.1003988107
30. Shih HY, Sciume G, Mikami Y, Guo L, Sun HW, Brooks SR, et al. Developmental regulation of interleukin-13-expressing innate lymphoid cells in autoimmunity: emerging regulators in rheumatic diseases. Nat Rev Rheumatol (2017) 13:64–73. doi:10.1038/nrrheum.2016.218
31. Moro K, Yamada T, Tanabe M, Takeuchi T, Iwao T, Kawamoto H, et al. Innate production of TH2 cytokines by adipose tissue-associated c-Kit(+)/Sca-1(+) lymphoid cells. Nature (2010) 463:540–4. doi:10.1038/nature08636
32. Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TK, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature (2010) 464:1367–70. doi:10.1038/nature08900
33. Fallon PG, Ballantyne SJ, Mangan NE, Barlow JL, Dasvarma A, Hewett DR, et al. Identification of an interleukin (IL)-25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsion. J Exp Med (2006) 203:1105–16. doi:10.1084/jem.20051615
34. Chang YJ, Kim HY, Albacker LA, Baumgarth N, McKenzie AN, Smith DE, et al. Identification of a conserved GATA3 response element upstream proximal from the interleukin-13 gene locus. J Biol Chem (2002) 277:42399–408. doi:10.1074/jbc.M203876200
35. Tanaka S, Motomura Y, Suzuki Y, Yagi R, Inoue H, Miyatake S, et al. The enhancer HS2 critically regulates GATA-3-mediated IL4 transcription in T(H)2 cells. Nat Immunol (2011) 12:77–85. doi:10.1038/ni.1966
36. Hu G, Tang Q, Sharma S, Yu F, Escobar TM, Muljo SA, et al. Expression and regulation of intergenic long noncoding RNAs during T cell development and differentiation. Nat Immunol (2013) 14:1190–8. doi:10.1038/ni.2712
37. Shih HY, Sciume G, Mikami Y, Guo L, Sun HW, Brooks SR, et al. Developmental regulation of interleukin-13-expressing innate lymphoid cells. Cell (2016) 165:1120–33. doi:10.1016/j.cell.2016.04.029
38. Hooyer T, Klose CS, Souabni A, Turqietti-Neves A, Pfeifer D, Rawlins EL, et al. The transcription factor GATA-3 controls cell fate and maintenance of type 2 innate lymphoid cells. Immunity (2012) 37:634–48. doi:10.1016/j.immuni.2012.06.020
39. Mjosberg J, Bernink J, Golebski K, Karrich JJ, Peters CP, Blom B, et al. The transcription factor GATA3 is essential for the function of human type 2 innate lymphoid cells. Immunity (2012) 37:649–59. doi:10.1016/j.immuni.2012.08.015
40. Yagi R, Zheng C, Northrup DL, Yu F, Bouladoux N, Spencer S, et al. The transcription factor GATA3 is critical for the development of all IL-7Ralpha-expressing innate lymphoid cells. Immunity (2014) 40:378–88. doi:10.1016/j.immuni.2014.01.012
41. Klein Wolterink RG, Serafini N, van Nimwegen M, Vosshenrich CA, de Bruijn MJ, Fonseca Pereira D, et al. Essential, dose-dependent role for the transcription factor GATA3 in the development of IL-5+ and IL-13+ type 2 innate lymphoid cells. Proc Natl Acad Sci U S A (2013) 110:10240–5. doi:10.1073/pnas.1217581110
42. Yang Q, Monticelli LA, Saenz SA, Chi AW, Sonnenberg GF, Tang J, et al. The T cell factor 1 is required for group 2 innate lymphoid cell generation. Immunity (2013) 38:694–704. doi:10.1016/j.immuni.2012.12.003
43. Furusawa J, Moro K, Motomura Y, Okamoto K, Zhu J, Takayangi H, et al. Critical role of p38 and GATA3 in natural helper cell function. J Immunol (2013) 191:1818–26. doi:10.4049/jimmunol.1300379
44. Zheng C, Cui K, Wilhelm C, Hu G, Mao K, Belkaid Y, et al. Group 3 innate lymphoid cells continuously require the transcription factor GATA-3 after commitment. Nat Immunol (2016) 17:169–78. doi:10.1038/ni.3318
45. Ho IC, Tai TS, Pai SY. GATA3 and the T-cell lineage: essential functions before and after T-helper-2-cell differentiation. Nat Rev Immunol (2009) 9:125–35. doi:10.1038/nri2476
46. Tindelans M, Serafini N, Di Santo JP, Hendriks RW. GATA-3 function in innate and adaptive immunity. Immunity (2014) 41:191–206. doi:10.1016/j.immuni.2014.06.006
47. Ting CN, Olson MC, Barton KP, Leiden JM. Transcription factor GATA3 is required for development of the T-cell lineage. Nature (1996) 384:474–8. doi:10.1038/384474a0
48. Pai SY, Truitt ML, Ting CN, Leiden JM, Glimcher LH, Ho IC. Critical roles for transcription factor GATA3 in thymocyte development. Immunity (2003) 19:863–75. doi:10.1016/S1074-7613(03)00328-5
63. Wang L, Wildt KE, Zhu J, Zhang X, Feigenbaum L, Tessarollo L, et al. Distinct functions for the transcription factors GATA-3 and ThPOK during intra-thymic differentiation of CD4(+)/T cells. Nat Immunol (2008) 9:1122–30. doi:10.1038/ni.1647
64. Hernandez-Hoyos G, Anderson MK, Wang C, Rothenberg EV, Alberola-Ila I. GATA-3 expression is controlled by TCR signals and regulates CD4/CD8 differentiation. Immunity (2003) 19:83–94. doi:10.1016/S1074-7613(03)00176-6
65. Zhu J. GATA3 regulates the development and functions of innate lymphoid cell subsets at multiple stages. Front Immunol (2017) 8:1571. doi:10.3389/fimmu.2017.01571
66. Wohlfert EA, Grainger JR, Bouladoux N, Kongel JE, Oldenhove G, Ribeiro CH, et al. GATA3 controls Foxp3(+) regulatory T cell fate during inflammation in mice. J Clin Invest (2011) 121:4503–15. doi:10.1172/JCI57456
67. Zheng Y, Josewicze S, Chaudhry A, Peng XP, Forbush K, Rudensky AY. Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature (2010) 463:808–12. doi:10.1038/nature08750
68. Wang Y, Su MA, Wan YY. An essential role of the transcription factor GATA-3 for the function of regulatory T cells. Immunity (2011) 35:337–48. doi:10.1016/j.immuni.2011.08.012
69. Rudra D, deRoos P, Chaudhry A, Niec RE, Arvey A, Samstein RM, et al. GATA-3 promotes maturation, IFN-gamma production, and liver-specific homing of NK cells. Immunity (2003) 19:701–11. doi:10.1016/S1074-7613(03)00177-4
70. Yu F, Sharma S, Edwards J, Feigenbaum L, Zhu J. Dynamic expression of transcription factors T-bet and GATA-3 by regulatory T cells maintains immunotolerance. Nat Immunol (2015) 16:197–206. doi:10.1038/ni.3053
71. Noval Rivas M, Burton OT, Wise P, Charbonnier LM, Georgiev P, Oettgen HC, et al. Regulatory T cell reprogramming toward a Th2-like lineage impairs oral tolerance and promotes food allergy. Immunity (2015) 42:512–23. doi:10.1016/j.immuni.2015.02.004
72. Samson SI, Richard O, Tavian M, Ranson T, Vosshenrich CA, Colucci P, et al. GATA-3 promotes maturation, IFN-gamma production, and liver-specific homing of NK cells. Immunity (2003) 19:701–11. doi:10.1016/S1074-7613(03)00294-2
73. Vosshenrich CA, Garcia-Ojeda ME, Samson-Villeger SI, Pasqualeto V, Enault L, Richard-Le Goof O, et al. A thymic pathway of mouse natural killer cell development characterized by expression of GATA-3 and CD127. Nat Immunol (2006) 7:1217–24. doi:10.1038/ni.1395
74. Kim PJ, Pais YJ, Brigl M, Besra GS, Gumperz J, Ho IC. GATA-3 regulates the development and function of invariant NKT cells. J Immunol (2006) 177:6650–9. doi:10.4049/jimmunol.177.10.6650
75. Lee YJ, Holzapfel KL, Zhu J, Jameson SC, Hoggquist KA. Steady-state production of IFN-gamma modulates immunity in mouse strains and is determined by lineage diversity of iNKT cells. Nat Immunol (2013) 14:1146–54. doi:10.1038/ni.2731
76. Wang Y, Misumi I, Gu AD, Curtis TA, Su L, Whitmire JK, et al. GATA-3 controls the maintenance and proliferation of T cells downstream of TCR and cytokine signaling. Nat Immunol (2013) 14:714–22. doi:10.1038/ni.2623
77. Yang Q, Li F, Harly C, Xing S, Ye L, Xia X, et al. TCF-1 upregulation identifies early innate lymphoid progenitors in the bone marrow. Nat Immunol (2015) 16:1044–50. doi:10.1038/ni.3248
78. Seehus CR, Allahramd P, de la Torre B, Iliev ID, Spurka L, Funari VA, et al. The development of innate lymphoid cells requires TOX-dependent generation of a common innate lymphoid progenitor. Nat Immunol (2015) 16:599–608. doi:10.1038/ni.3168
79. Zook EC, Kee BL. Development of innate lymphoid cells. Nat Immunol (2016) 17:775–82. doi:10.1038/ni.3481
80. Zhong C, Zhu J. Bcl11b drives the birth of ILC2 innate lymphocytes. J Exp Med (2015) 212:828. doi:10.1084/jem.20126081
81. Li J, Leid M, Rothenberg EV. An early T cell lineage commitment checkpoint dependent on the transcription factor Bcl11b. Science (2010) 329:89–93. doi:10.1126/science.1188989
82. Walker JA, Oliphant CJ, Englezakis A, Yu Y, Clare S, Rodewald HR, et al. Bcl11b is essential for group 2 innate lymphoid cell development. J Exp Med (2015) 212:875–82. doi:10.1084/jem.20142224
83. Yu Y, Wang C, Clare S, Wang J, Lee SC, Brandt C. et al. The transcription factor Bcl11b is specifically expressed in group 2 innate lymphoid cells and is essential for their development. J Exp Med (2015) 212:865–74. doi:10.1084/jem.20142318
84. Califano D, Cho JJ, Uddin MN, Lorentzen KJ, Yang Q, Bhandoola A, et al. Transcription factor Bcl11b controls identity and function of mature type 2 innate lymphoid cells. Immunity (2015)43:354–68. doi:10.1016/j.immuni.2015.07.005
85. Fang D, Cui K, Hu G, Gurram RK, Zhong C, Oler AJ, et al. Bcl11b, a novel GATA3-interacting protein, suppresses Th1 while limiting Th2 cell differentiation. J Exp Med (2018) 215. doi:10.1084/jem.20171127
86. Hwang ES, Szabo SJ, Schwartzberg PL, Glimcher LH. T helper cell fate specified by kinase-mediated interaction of T-bet with GATA-3. Science (2005) 307:430–3. doi:10.1126/science.1103336
87. Usui T, Preiss JC, Kanno Y, Yao ZJ, Bream H, O’Shea JJ, et al. T-bet regulates Th1 responses through essential effects on GATA-3 function rather than on IFNG gene acetylation and transcription. J Exp Med (2006) 203:754–754. doi:10.1084/jem.20052165
88. Kanhere A, Hertweck A, Batlia U, Gokmen MR, Perucha E, Jackson I, et al. T-bet and GATA3 orchestrate Th1 and Th2 differentiation through lineage-specific targeting of distal regulatory elements. Nat Commun (2012) 3:1268. doi:10.1038/ncomms2260
89. Jenner RG, Townsend MJ, Jackson I, Sun K, Bouwman RD, Young RA, et al. The transcription factors T-bet and GATA-3 control alternative pathways of T-cell differentiation through a shared set of target genes. Proc Natl Acad Sci U S A (2009) 106:17876–81. doi:10.1073/pnas.0909357106
90. Zhu J, Jankovic D, Oler AJ, Wei G, Sharma S, Hu G, et al. The transcription factor T-bet is induced by multiple pathways and prevents an endogenous Th2 cell program during Th1 cell responses. Immunity (2012) 37:680–703. doi:10.1016/j.immuni.2012.09.007
91. Peine M, Rausch S, Helmstetter C, Frohlich A, Hegazy AN, Kuhl AA, et al. Stable T-bet(+)/GATA3(-) Th1/Th2 hybrid cells arise in vivo, can develop directly from naive precursors, and limit immunopathologic inflammation. PLoS Biol (2013) 11:e1001633. doi:10.1371/journal.pbio.1001633
92. Usui T, Nishikomori R, Kitani A, Strober W. GATA-3 suppresses Th1 development by downregulation of Stat4 and not through effects on IL-12Rbeta2 chain or T-bet. J Exp Med (2008) 209:939–944. doi:10.1084/jem.20080507-8

Conflict of Interest Statement: The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.